Of the more than 38,000 Americans diagnosed with renal cell carcinoma (RCC) each year, approximately 20 percent have non-clear cell forms of the disease. New findings shows that a non-clear cell form of kidney cancer known as papillary RCC, which accounts for 12 percent of all RCC, responds differently to sunitinib – a standard frontline treatment for RCC.
In a small but decisive Phase II trial, the researchers found that sunitinib was not effective in patients with this form of the disease. The terms clear- and non-clear cell refer to the general appearance of the cancer cells under a microscope.
"With clear-cell RCC, there is a lot of data," said Fox Chase Cancer Center medical oncologist Elizabeth R. Plimack, M.D., M.S., who led the study while at University of Texas MD Anderson Cancer Center and will report the results at the 46th Annual Meeting of the American Society of Clinical Oncology on Monday, June 7.
"Most large studies have involved primarily or exclusively clear-cell patients. Because data on the behavior of non-clear cell kidney cancer is lacking, the disease has been treated similarly to clear cell. Now that we're taking a hard look at how sunitinib works on non-clear cell kidney cancer, we're seeing a lot of differences between the two diseases," says Plimack.
Working with investigators at the University of Texas MD Anderson Cancer Center, Plimack and fellow researchers examined the response and survival rates of 23 patients with papillary RCC who were treated with sunitinib.
The study built upon prior research that showed a high response rate and improved progression-free survival and overall survival in patients with clear-cell RCC who used sunitinib to interfere with the growth of cancers cells, either slowing or stopping the development of tumors.
In the current study, patients with papillary RCC were treated with sunitinib according to a two-stage design. Following the sunitinib regimen, Plimack and her colleagues found no major responses, a median progression free survival of 1.6 months and median overall survival of 10.8 months. The best response was stable disease in eight patients. The results underscore the need to develop more effective therapies for papillary RCC.
"We really need to investigate papillary renal cell carcinoma separately from clear-cell renal cell carcinoma and aggressively pursue new agents for this rare but distinct subtype of renal cell cancer," says Plimack.
Co-authors on the reported study included MD Anderson researchers Eric Jonasch, B Nebiyou Bekele, Xin-Qiao Zhang, C Ng, and NM Tannir. Funding for this investigator-initiated study was provided by Pfizer.
Fox Chase Cancer Center is one of the leading cancer research and treatment centers in the United States. Founded in 1904 in Philadelphia as one of the nation's first cancer hospitals, Fox Chase was also among the first institutions to be designated a National Cancer Institute Comprehensive Cancer Center in 1974. Fox Chase researchers have won the highest awards in their fields, including two Nobel Prizes. Fox Chase physicians are also routinely recognized in national rankings, and the Center's nursing program has received the Magnet status for excellence three consecutive times. Today, Fox Chase conducts a broad array of nationally competitive basic, translational, and clinical research, with special programs in cancer prevention, detection, survivorship, and community outreach. For more information, visit Fox Chase's Web site at www.fccc.org or call 1-888-FOX CHASE or (1-888-369-2427).
Diana Quattrone | EurekAlert!
Nanoparticle Exposure Can Awaken Dormant Viruses in the Lungs
16.01.2017 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt
Cholera bacteria infect more effectively with a simple twist of shape
13.01.2017 | Princeton University
Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.
While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...
Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales
Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...
Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.
As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...
At TU Wien, an alternative for resource intensive formwork for the construction of concrete domes was developed. It is now used in a test dome for the Austrian Federal Railways Infrastructure (ÖBB Infrastruktur).
Concrete shells are efficient structures, but not very resource efficient. The formwork for the construction of concrete domes alone requires a high amount of...
Many pathogens use certain sugar compounds from their host to help conceal themselves against the immune system. Scientists at the University of Bonn have now, in cooperation with researchers at the University of York in the United Kingdom, analyzed the dynamics of a bacterial molecule that is involved in this process. They demonstrate that the protein grabs onto the sugar molecule with a Pac Man-like chewing motion and holds it until it can be used. Their results could help design therapeutics that could make the protein poorer at grabbing and holding and hence compromise the pathogen in the host. The study has now been published in “Biophysical Journal”.
The cells of the mouth, nose and intestinal mucosa produce large quantities of a chemical called sialic acid. Many bacteria possess a special transport system...
10.01.2017 | Event News
09.01.2017 | Event News
05.01.2017 | Event News
17.01.2017 | Earth Sciences
17.01.2017 | Materials Sciences
17.01.2017 | Architecture and Construction